NASDAQ:OVID

Ovid Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy OVID

*Your capital is at risk

$2.40

-0.0800 (-3.23%)

At Close: Jun 05, 2026

Ovid Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.22. In total, the insiders bought 15.95M and sold 39.88K OVID shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	94.22
● Buy	15.95M shares
● Sell	39.88K shares
92% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Feb 26, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 94.22. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (92% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 09, 2024 Buy	Employee Stock Option (right to buy)	Alexander Margaret A. President And COO	CEO / President	100 000 Value: $272.0K
Sep 09, 2024 Buy	Common Stock	Alexander Margaret A. President And COO	CEO / President	0 Value: $0
Sep 09, 2024 Buy	Employee Stock Option (right to buy) A-Award	Alexander Margaret A. President And COO	CEO / President	140 000 Value: $149.8K
Jul 30, 2024 Buy	Employee Stock Option (right to buy) A-Award	Rona Jeffrey A Cbfo	Officer	315 000 Value: $329.2K
Jul 30, 2024 Buy	Employee Stock Option (right to buy) A-Award	Rona Jeffrey A Cbfo	Officer	315 000 Value: $329.2K
Mar 18, 2024 Buy	Common Stock P-Purchase	Levin Jeremy M CEO	CEO / President	18 248 Value: $50.4K
Mar 18, 2024 Buy	Common Stock P-Purchase	Levin Jeremy M CEO	CEO / President	18 248 Value: $50.4K
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Tardio Jason Chief Operating Officer	C-Suite Officer	168 750 Value: $621.0K
Feb 22, 2024 Buy	Common Stock A-Award	Tardio Jason Chief Operating Officer	C-Suite Officer	28 125 Value: $0
Feb 22, 2024 Buy	Common Stock A-Award	Rona Jeffrey A Cbfo	Officer	28 125 Value: $0
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Rona Jeffrey A Cbfo	Officer	168 750 Value: $621.0K
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Poole Robert Michael Director	Director	30 000 Value: $110.4K
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Perone Thomas Michael General Counsel, Secretary	Officer	168 750 Value: $621.0K
Feb 22, 2024 Buy	Common Stock A-Award	Perone Thomas Michael General Counsel, Secretary	Officer	28 125 Value: $0
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Bernstein Karen Director	Director	30 000 Value: $110.4K
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Duncan Barbara Gayle Director	Director	30 000 Value: $110.4K
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Fitzgerald Kevin Joseph Director	Director	30 000 Value: $110.4K
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Friedman Bart Director	Director	30 000 Value: $110.4K
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Levin Jeremy M CEO	CEO / President	700 000 Value: $2.58M
Feb 22, 2024 Buy	Common Stock A-Award	Perone Thomas Michael General Counsel, Secretary	Officer	28 125 Value: $0
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Perone Thomas Michael General Counsel, Secretary	Officer	168 750 Value: $621.0K
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Poole Robert Michael Director	Director	30 000 Value: $110.4K
Feb 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Rona Jeffrey A Cbfo	Officer	168 750 Value: $621.0K
Feb 22, 2024 Buy	Common Stock A-Award	Rona Jeffrey A Cbfo	Officer	28 125 Value: $0
Feb 22, 2024 Buy	Common Stock A-Award	Tardio Jason Chief Operating Officer	C-Suite Officer	28 125 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OVID THERAPEUTICS INC

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule...

Read Full Profile Here